Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Agenus Inc.

Other

Sloan-kettering Institute for Cancer Research

Institute of Molecular Biology and Genetics National Academy of Science of Ukraine

Cornell Research Foundation Inc.

Oxford University Innovation Limited

The University of Birmingham

Abbott Laboratories Corporation

Yale University

Institute for Molecular Biology and Genetics National Academy of Science of Ukraine

The Chancellor, Masters and Scholars of the University of Oxford

Institute of Molecular Biology and Genetics National Academy of Sciences of Ukraine

Gerd J Ritter

Taha Merghoub

Marc A Van Dijk

David Schaer

Lloyd J Old

Nicholas Stuart Wilson

David Adam Savitsky

Jedd David Wolchok

Volker Seibert

Cornelia Anne Mundt

Dennis John Underwood

Takemasa Tsuji

Olivier Léger

Ekaterina Vladimirovna Breous-Nystrom

Daniel Hirschhorn-Cymerman

Sydney Welt

Richard R Schmidt

Roberta Zappasodi

Matthew J Scanlan

Jeremy Dale Waight

Yao-tseng Chen

Ali O Gure

Jan Wouter Drijfhout

Alexander Knuth

Mark Arthur Findeis

Jean-Marie Cuillerot

Achim Jungbluth

Igor Proscurshim

Olga Shebanova

Anne Murray

Hao Tang

George Mark

Kenneth O Lloyd

Ivan Tarasovich Gout

Elke Jäger

Valeriy Filonenko

Ramziya Kiyamova

Beatrice Yin

Serhiy Souchelnytskiy

Lloyd Old

Gurdyal S Besra

Vincenzo Cerundolo

Edouard Collins Nice

Leonard Cohen

Gopal Reddy

Rengarajan Balamurugan

Mariolina Salio

Ana M Gonzalez

Jonathan Silk

Carlos F Barbas, Iii

Richard John Simpson

Elisabeth Stockert

Christoph Rader

Antony Wilks Burgess

Webster K Cavenee

Christoph Renner

Peter Smith-Jones

Enver Arslantas

Cameron Johnstone

Hong Ji

R L Moritz

Mary John

Elizabeth Carswell Richards

Clarence Williams, Jr

Julio C Castro-Palomino

Sara J White

Joan K Heath

Rikke Bæk Holmgaard

Rikke Baek Holmgaard

Philip O Livingston

Herbert F Oettgen

Con Panousis

Jorge E Galan

Elke J&auml;ger

Terrance Grant Johns

Sacha Gnjatic

Cynthia H Scanlan, Legal Representative

Andrew Mark Scott

Anthony W Burgess

Huei-Jen Su Huang

Bruno Catimel

Andreas Doll

B Catimel

Hiroyoshi Nishikawa

Peter Collins

Nancy Kemeny

Elizabeth Stockert

Gurdyal Besra

Terrance Grant Jonhs

Huei-Jen Huang

Anthony Wilks Burgess

Marc Van Dijk

Volker Siebert

Olivier Leger

Nicolas S Wilson

The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CTLA-4 antibodies and methods of use thereof

Provided are antibodies that specifically bind to CTLA-4 and/or PD-1 and antagonize CTLA-4 and/or PD-1 function. Also provided are pharmaceutical compositions and kits comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies either alone or in combination.

Antibodies and methods of use thereof

The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.

Anti-GITR antibodies and methods of use thereof

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

Methods of administering anti-OX40 antibodies

The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies. The antibodies disclosed herein modulate OX40 and/or GITR activity e.g., enhance, activate, induce, reduce, deactivate, or inhibit OX40 and/or GITR activity. The present disclosure also provides methods for treating disorders, such as cancer, autoimmune diseases or disorders, or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and/or human GITR and modulates OX40 and/or GITR activity.

Anti-OX40 antibodies and anti-GITR antibodies

The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-PD-1 antibodies and methods of use thereof

Vectors comprising nucleic acids encoding anti-OX40 antibodies

The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-OX40 antibodies

Growing community of inventors

New York, NY, United States of America

Gerd J Ritter